Alexander has two decades of experience in biotechnology. Credit: Flagship Pioneering/PR Newswire.

Flagship Pioneering-founded Valo Health has announced the appointment of Dr Brian Alexander as its new CEO.

Additionally, Alexander will serve as Flagship Pioneering’s CEO-partner.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

With 20 years of experience in biotechnology and medical leadership, he aims to enhance Valo Health’s mission to accelerate drug discovery and development.

Alexan­der said: “I am deeply honoured to join Flag­ship Pio­neer­ing and Valo Health at such a piv­otal time for the com­pa­ny. 

​“Our mis­sion at Valo is to accel­er­ate the dis­cov­ery and devel­op­ment of bet­ter medicines for patients by fun­da­men­tal­ly chang­ing the tra­di­tion­al dis­cov­ery par­a­digm, and I am excit­ed to lead and work with the amaz­ing tal­ent at Valo to deliv­er mean­ing­ful advance­ments for patients using the pow­er of AI and human-cen­tric data.”

His previous roles include CEO of Foundation Medicine and senior vice-president of research and development and head of Boston Roche Innovation Center for Roche/Genentech.

At Foundation Medicine, Alexander utilised molecular information to enhance cancer care and clinical decision-making.

Meanwhile, he focused on clinical development at Roche/Genentech, with machine learning, data science, and AI utilisation.

Earlier, he co-founded the Global Coalition for Adaptive Research to expedite treatment discovery and development for rare diseases through clinical trials.

Alexander was also the Harvard/MIT Center for Regulatory Science’s founding director.

At Harvard Medical School, he served as an associate professor and was a radiation oncologist at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital.

Valo and Flag­ship Pio­neer­ing gen­er­al part­ner and exec­u­tive chair Paul Bion­di said: “I am delight­ed to wel­come Bri­an Alexan­der as the CEO of Valo Health and a Flag­ship Pio­neer­ing CEO-part­ner. 

​“Brian’s proven lead­er­ship across biotech­nol­o­gy makes him well-posi­tioned to guide Valo into its next chap­ter of growth, as it har­ness­es AI-dri­ven tech­nol­o­gy and high-qual­i­ty patient data to dis­cov­er and devel­op life-chang­ing medicines.”